康达心口服液对心肾综合征大鼠氧化应激的影响

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (728 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨康达心口服液对心肾综合征（CRS）大鼠的影响及潜在机制。方法将60 只SD 大鼠随机分为5组：假手术（sham）组、心力衰竭（HF）组、CRS 组、HF 干预（HF+I）组、CRS 干预（CRS+I）组，通过心脏彩超测量各组大鼠左室射血分数（LVEF）、左室缩短分数（FS）；通过ELISA 法检测血清氨基末端脑钠肽前体（NT-proBNP）、肌酐（Cr）、尿素氮（Bun）、总抗氧化能力（T-AOC）、超氧化物歧化酶（SOD）、丙二醛（MDA）水平。结果 HF 组、HF+I 组、CRS 组、CRS+I 组大鼠的FS 及LVEF 值低于sham 组，血清NT-proBNP 水平高于sham 组，差异有统计学意义（P<0.05）。HF+I 组的FS 及LVEF 值高于HF 组，NT-proBNP 水平低于HF 组，差异有统计学意义（P<0.05）。CRS+I 组的FS 及LVEF 值高于CRS 组，NT-proBNP 水平低于CRS 组，差异有统计学意义（P<0.05）。CRS 组、CRS+I 组大鼠的血清Cr 及Bun 水平高于sham 组，差异有统计学意义（P<0.05）。CRS+I 组的血清Cr 及Bun 水平低于CRS 组，差异有统计学意义（P<0.05）。HF 组、HF+I 组、CRS 组、CRS+I 组的血清T-AOC、SOD 水平低于sham 组，MDA 水平高于sham 组，差异有统计学意义（P<0.05）。HF+I 组大鼠的血清T-AOC、SOD 水平高于HF 组、MDA 水平低于HF组，差异有统计学意义（P<0.05）。CRS+I 组大鼠的血清TAOC、SOD 水平高于CRS 组，MDA 水平低于CRS 组，差异有统计学意义（P<0.05）。结论康达心改善CRS 大鼠心功能的效应，可能是通过提高抗氧化能力、抑制氧化应激实现的。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴翔
	张婷婷
	熊尚全

关键词 ：康达心口服液, 心肾综合征, 氧化应激, 总抗氧化能力, 超氧化物歧化酶

Abstract：Objective To investigate the effect and potential mechanism of Kangdaxin Oral Liquid on cardiorenal syndrome (CRS) rats.Methods Sixty SD rats were randomly divided into 5 groups:sham operation (sham) group,heart failure (HF) group,CRS group,HF+intervention (I) group and CRS+I group.Left ventricular ejection fraction (LVEF)and left ventricular shortening fraction (FS) were measured by cardiac color ultrasound.The levels of serum N-terminal pro-B type natriuretic peptide (NT-proBNP),creatinine (Cr),urea nitrogen (Bun),total antioxidant capacity (TAOC),superoxide dismutase (SOD),malondialdehyde (MDA) were determined by ELISA.Results The FS and LVEF values of rats in HF group,HF+I group,CRS group and CRS+I group were lower than those in sham group,and serum NT-proBNP level was higher than that in sham group,the differences were statistically significant (P<0.05).The FS and LVEF values in HF+I group were higher than those in HF group,and the level of NT-proBNP was lower than that in HF group,the differences were statistically significant (P<0.05).The FS and LVEF values of CRS+I group were higher than those of CRS group,and the level of NT-proBNP was lower than that of CRS group,the differences were statistically significant (P<0.05).The levels of serum Cr and Bun in CRS group and CRS+I group were higher than those in sham group,and the differences were statistically significant (P<0.05).The levels of serum Cr and Bun in CRS+I group were lower than those in CRS group,the differences were statistically significant (P<0.05).Serum TAOC and SOD levels in HF group,HF+I group,CRS group and CRS+I group were lower than those in sham group,while MDA level was higher than that in sham group,the differences were statistically significant (P<0.05).Serum T-AOC and SOD levels in HF+I group were higher than those in HF group,while MDA levels were lower than those in HF group,the differences were statistically significant (P<0.05).Serum T-AOC and SOD levels in CRS+I group were higher than those in CRS group,while MDA levels were lower than those in CRS group,the differences were statistically significant (P<0.05).Conclusion Kangdaxin Oral Liquid may improve cardiac function in rats with cardiorenal syndrome by promoting antioxidant capacity and suppressing oxidative stress.

Key words： Kangdaxin Oral Liquid Cardionrenal syndrome Oxidative stress Total antioxidant capacity Superoxide dismutase

基金资助:福建省教育厅中青年教师教育科研项目（JAT17 0281）

作者简介: 吴翔（1977-），男，博士，副主任医师，研究方向：心力衰竭与心律失常的发病机制及治疗

引用本文:

吴翔；张婷婷；熊尚全. 康达心口服液对心肾综合征大鼠氧化应激的影响[J]. 中国当代医药, 2022, 29(14): 10-13.
WU Xiang；ZHANG Tingting；XIONG Shangquan. Effect of Kangdaxin Oral Liquid on oxidative stress in rats with cardiorenal syndrome. 中国当代医药, 2022, 29(14): 10-13.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I14/10

[16]	吴翔，熊尚全，郑峰，等.康达心口服液改善2 型心肾综合征患者心肾功能作用的分析[J].福建医药杂志，2016，38（3）：88-90.
[1]	Kumar U，Wettersten N，Garimella PS.Cardiorenal Syndrome：Pathophysiology[J].Cardiol Clin，2019，37（3）：251-265.
[2]	Costanzo MR.The Cardiorenal Syndrome in Heart Failure[J].Heart Fail Clin，2020，16（1）：81-97.
[3]	Raina R，Nair N，Chakraborty R，et al.An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome[J].Cardiol Res，2020，11（2）：76-88.
[4]	Jentzer JC，Bihorac A，Brusca SB，et al.Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council.Contemporary Management of Severe?Acute Kidney Injury and Refractory Cardiorenal Syndrome：JACC Council Perspectives[J].J Am Coll Cardiol，2020，76（9）：1084-1101.
[5]	Hatamizadeh P.Cardiorenal Syndrome：An Important Subject in Nephrocardiology[J].Cardiol Clin，2021，39（3）：455-469.
[6]	吴翔，宫玉榕，杨直，等.康达心对心肾综合征大鼠心脏保护效应的机制研究[J].中国临床药理学杂志，2019，35（7）：643-646.
[7]	Rossi M，Johnson DW，Morrison M，et al.SYNbiotics Easing Renal failure by improving Gut microbiologY （SYNERGY）：a protocol of placebo-controlled randomised cross-over trial[J].BMC Nephrol，2019，4（15）：106-112.
[8]	Goffredo G，Barone R，Di Terlizzi V，et al.Biomarkers in Cardiorenal Syndrome[J].J Clin Med，2021，10（15）：3433.
[9]	Zhao Y，Wang C，Hong X，et al.Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome[J].Kidney Int，2019，95（4）：815-829.
[10]	Gembillo G，Visconti L，Giusti MA，et al.Cardiorenal Syndrome：New Pathways and Novel Biomarkers[J].Biomolecules，2021，11（11）：1581-1588.
[13]	郑峰，郑伯仁，林超，等.慢性心力衰竭患者基质金属蛋白酶-9 的变化及康达心的影响[J].中国老年保健医学，2012，10（4）：57-59.
[14]	吴翔，张婷婷，乔建峰，等.康达心口服液对射血分数保留心力衰竭大鼠心肌纤维化的影响[J].中西医结合心脑血管病杂志，2020，18（24）：4149-4151.
[15]	江灵艳.康达心对阳虚水泛型慢性心力衰竭患者GDF-15 的影响及疗效观察[D].福州：福建中医药大学，2020.
[11]	Marsault E，Llorens-Cortes C，Iturrioz X，et al.The apelinergic system：a perspective on challenges and opportunities in cardiovascular and metabolic disorders[J].Ann N Y Acad Sci，2019，1455（1）：12-33.
[12]	Cowger JA，Radjef R.Advanced Heart Failure Therapies and Cardiorenal Syndrome[J].Adv Chronic Kidney Dis，2020，25（5）：443-453.
[17]	Yenkoyan K，Harutyunyan H，Harutyunyan A.A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders[J].Free Radic Biol Med，2018，1（12）：85-95.
[18]	Majidi Z，Hosseinkhani S，Amiri-Dashatan N，et al.Effect of rosiglitazone on circulating malondialdehyde （MDA）level in diabetes based on a systematic review and metaanalysis of eight clinical trials[J].J Investig Med，2021，69（3）：697-703.